POLB 001 poster to be presented at EHA 2026

AI SummaryClose X

Poolbeg Pharma plc will present data on its drug candidate POLB 001 at the European Hematology Association Congress, demonstrating its potential to prevent cancer immunotherapy-induced Cytokine Release Syndrome (CRS) by reducing key cytokines like TNF, IFNγ, and IL-6 in vivo, without impairing bispecific antibody-induced tumor cell killing in vitro. This presentation, scheduled for Saturday, June 13, 2026, in Stockholm, highlights POLB 001's potential to improve patient quality of life and expand access to life-saving cancer immunotherapies.

Disclaimer*

UK 100

Latest directors dealings